Korea Pharmaceutical and Bio-Pharma Manufacturers Association Supports 210 Korean Companies’ Participation in Bio-Europe

Discusses cooperation with cluster representatives
Also holds biotech IR session

More than 210 Korean companies took part in Bio-Europe 2026, Europe’s largest pharmaceutical and biotech exhibition. By number of participating companies, Korea ranked fourth, after Germany, the United States and the United Kingdom.

Noh Yeonhong, chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, delivers welcoming remarks on the 9th. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

On November 13, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association said it had supported Korean companies’ overseas expansion and broadened the basis for cooperation with major foreign organizations at Bio-Europe 2026, held in Cologne, Germany, from November 9 to 11. This year’s event drew more than 3,100 companies from 65 countries around the world.

During the event, the association met with representatives of major overseas pharmaceutical and biotech associations and clusters, including the Biotechnology Innovation Organization (BIO), to discuss ways to support Korean companies’ global expansion and business cooperation. In particular, it discussed ways to create more concrete business opportunities with BIO through networking and business matching between the two organizations’ member companies. The parties also agreed to increase information sharing on key policy and regulatory issues in the global pharmaceutical and biotech industry and to consider cooperation on joint responses.

The association also held events to expand business opportunities for Korean companies. On November 9, it hosted a “Korea Night” reception with the Korea Health Industry Development Institute, the National Institute of Toxicological Research, and the Daegu-Gyeongbuk Medical Innovation Foundation. More than 200 industry representatives from Korea and abroad attended, with international attendees making up 36% of the total, a record-high proportion. The association also operated a “Korea Pavilion” at the venue to facilitate business meetings between Korean companies and overseas representatives.

On November 10, the association held an investor relations (IR) session to introduce promising Korean biotech companies to an international audience. Four companies—Mbeuriks, Makeuhelcheu, Poteurei, and Onkoin saiteu—participated and presented key technologies, including next-generation gene therapies such as chimeric antigen receptor T-cell (CAR-T) therapies, precision medicine using artificial intelligence (AI)-based spatial transcriptomics analysis, and natural killer (NK) cell-based immuno-oncology drugs. They then met with global pharmaceutical companies and investment experts to explore opportunities for overseas expansion and investment attraction.

Noh Yeonhong, chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, said, “For Korean pharmaceutical and biotech companies to demonstrate their competitiveness in the global market, it is important to secure opportunities for cooperation through ongoing exchanges with overseas companies and organizations, alongside excellent technological capabilities. Building on the global network we developed at Bio-Europe, we will actively support Korean companies in expanding overseas partnerships and identifying business opportunities.”

This content was produced with the assistance of AI translation services.